Cargando…

SARS-CoV-2 Infection Among Hospitalized Pregnant Women: Reasons for Admission and Pregnancy Characteristics — Eight U.S. Health Care Centers, March 1–May 30, 2020

Detalles Bibliográficos
Autores principales:	Panagiotakopoulos, Lakshmi, Myers, Tanya R., Gee, Julianne, Lipkind, Heather S., Kharbanda, Elyse O., Ryan, Denison S., Williams, Joshua T.B., Naleway, Allison L., Klein, Nicola P., Hambidge, Simon J., Jacobsen, Steven J., Glanz, Jason M., Jackson, Lisa A., Shimabukuro, Tom T., Weintraub, Eric S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Centers for Disease Control and Prevention 2020
Materias:	Full Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7727498/ https://www.ncbi.nlm.nih.gov/pubmed/32970660 http://dx.doi.org/10.15585/mmwr.mm6938e2

Ejemplares similares

Association of Inadvertent 9-Valent Human Papillomavirus Vaccine in Pregnancy With Spontaneous Abortion and Adverse Birth Outcomes
por: Kharbanda, Elyse O., et al.
Publicado: (2021)

Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination
por: DeSilva, Malini B., et al.
Publicado: (2023)

Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy
por: DeSilva, Malini, et al.
Publicado: (2022)

Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes
por: Greenberg, Victoria, et al.
Publicado: (2023)

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021
por: Shay, David K., et al.
Publicado: (2021)

Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults
por: Storms, Aaron D., et al.
Publicado: (2017)

Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination
por: Goddard, Kristin, et al.
Publicado: (2022)

COVID-19 Vaccination Coverage Among Insured Persons Aged ≥16 Years, by Race/Ethnicity and Other Selected Characteristics — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 15, 2021
por: Pingali, Cassandra, et al.
Publicado: (2021)

Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination
por: Naleway, Allison L., et al.
Publicado: (2021)

Receipt of COVID-19 Vaccine During Pregnancy and Preterm or Small-for-Gestational-Age at Birth — Eight Integrated Health Care Organizations, United States, December 15, 2020–July 22, 2021
por: Lipkind, Heather S., et al.
Publicado: (2022)

Eight Reasons for Planting an Orchard
Publicado: (1861)

Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged ≥12 Years with Presumed Immunocompromise Status — United States, January 12, 2022–March 28, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020–May 8, 2021
por: Razzaghi, Hilda, et al.
Publicado: (2021)

Safety Monitoring of COVID-19 mRNA Vaccine Second Booster Doses Among Adults Aged ≥50 Years — United States, March 29, 2022–July 10, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

1162. Influenza Vaccination Among Pregnant People in the Vaccine Safety Datalink, 2016-17 through 2022-23 Influenza Seasons
por: Irving, Stephanie, et al.
Publicado: (2023)

COVID-19 Booster Vaccination in Early Pregnancy and Surveillance for Spontaneous Abortion
por: Kharbanda, Elyse O., et al.
Publicado: (2023)

Reasons for admission to a general medical hospital for patients taking clozapine
por: Gee, Siobhan, et al.
Publicado: (2022)

Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions
por: Smith, Kristofer L, et al.
Publicado: (2014)

The v-safe after vaccination health checker: Active vaccine safety monitoring during CDC’s COVID-19 pandemic response
por: Myers, Tanya R., et al.
Publicado: (2023)

Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system
por: Chapin-Bardales, Johanna, et al.
Publicado: (2021)

Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022
por: Duffy, Jonathan, et al.
Publicado: (2022)

Beyond reason: eight great problems that reveal the limits of science
por: Dewdney, A K
Publicado: (2004)

Parkinson’s disease and the frequent reasons for emergency admission
por: Guneysel, Ozlem, et al.
Publicado: (2008)

Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US
por: Hause, Anne M., et al.
Publicado: (2022)

COVID-19 Vaccine Safety in Children Aged 5–11 Years — United States, November 3–December 19, 2021
por: Hause, Anne M., et al.
Publicado: (2021)

Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5–11 Years — United States, May 17–July 31, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5–11 Years — United States, October 12–January 1, 2023
por: Hause, Anne M., et al.
Publicado: (2023)

Hospital Admissions from Nursing Homes: Rates and Reasons
por: Krüger, Kjell, et al.
Publicado: (2011)

Length of stay and reason for admission in an adolescents inpatient unit
por: Taracena Cuerda, M., et al.
Publicado: (2022)

Estimated rates of influenza‐associated outpatient visits during 2001‐2010 in 6 US integrated healthcare delivery organizations
por: Zhou, Hong, et al.
Publicado: (2018)

U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines
por: Gubernot, Diane, et al.
Publicado: (2021)

Relative Risks of COVID-19–Associated Hospitalizations and Clinical Outcomes by Age and Race/Ethnicity—March 2020–March 2021
por: Bozio, Catherine H, et al.
Publicado: (2022)

COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months–5 Years — United States, June 18, 2022–August 21, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
por: Shimabukuro, Tom T., et al.
Publicado: (2021)

What physicians reason about during admission case review
por: Juma, Salina, et al.
Publicado: (2016)

Measuring Scientific Reasoning for Graduate Admissions in Psychology and Related Disciplines
por: Sternberg, Robert J., et al.
Publicado: (2017)

Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Persons Aged ≥12 Years — United States, August 31–October 23, 2022
por: Hause, Anne M., et al.
Publicado: (2022)

2763. Uptake and Safety of Measles-Mumps-Rubella (MMR) Vaccine in Adolescents and Adults in the Vaccine Safety Datalink
por: Hanson, Kayla E, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2dnfe9gn54sfum9ma4lloo1ar5